Medtronic Dirección
Dirección controles de criterios 2/4
El CEO de Medtronic es Geoff Martha , nombrado en Apr 2020, tiene una permanencia de 4.58 años. compensación anual total es $20.08M, compuesta por 6.7% salario y 93.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.006% de las acciones de la empresa, por valor de $6.49M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 7.8 años, respectivamente.
Información clave
Geoff Martha
Chief Executive Officer (CEO)
US$20.1m
Compensación total
| Porcentaje del salario del CEO | 6.7% |
| Permanencia del CEO | 4.6yrs |
| Participación del CEO | 0.006% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 7.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Nov 19Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns
Nov 08
Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)
Oct 31Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?
Oct 13Medtronic: Undervalued Dividend Aristocrat With High Margins
Oct 10An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued
Sep 30Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks
Sep 16Medtronic: An Undervalued Stock With Durable Competitive Advantages
Sep 16Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Sep 05Medtronic: Is The Company Back?
Aug 26Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?
Jan 16Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings
Dec 29Medtronic's (NYSE:MDT) Dividend Will Be $0.69
Dec 12Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes
Nov 19Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued
Oct 19Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Oct 04Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%
Sep 27Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Sep 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Oct 25 2024 | n/a | n/a | US$4b |
| Jul 26 2024 | n/a | n/a | US$4b |
| Apr 26 2024 | US$20m | US$1m | US$4b |
| Jan 26 2024 | n/a | n/a | US$4b |
| Oct 27 2023 | n/a | n/a | US$4b |
| Jul 28 2023 | n/a | n/a | US$4b |
| Apr 28 2023 | US$15m | US$1m | US$4b |
| Jan 27 2023 | n/a | n/a | US$4b |
| Oct 28 2022 | n/a | n/a | US$4b |
| Jul 29 2022 | n/a | n/a | US$5b |
| Apr 29 2022 | n/a | n/a | US$5b |
| Jan 28 2022 | n/a | n/a | US$5b |
| Oct 29 2021 | n/a | n/a | US$5b |
| Jul 30 2021 | n/a | n/a | US$4b |
| Apr 30 2021 | US$18m | US$1m | US$4b |
| Jan 29 2021 | n/a | n/a | US$3b |
| Oct 30 2020 | n/a | n/a | US$4b |
| Jul 31 2020 | n/a | n/a | US$4b |
| Apr 24 2020 | US$6m | US$905k | US$5b |
| Jan 24 2020 | n/a | n/a | US$5b |
| Oct 25 2019 | n/a | n/a | US$5b |
| Jul 26 2019 | n/a | n/a | US$4b |
| Apr 26 2019 | US$4m | US$693k | US$5b |
Compensación vs. Mercado: La compensación total de Geoff($USD20.08M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD12.73M).
Compensación vs. Ingresos: La compensación de Geoff ha aumentado más de un 20% en el último año.
CEO
Geoff Martha (54 yo)
4.6yrs
Permanencia
US$20,084,630
Compensación
Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Director of NextEra...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.6yrs | US$20.08m | 0.0060% $ 6.5m | |
| Executive VP & President of Cardiovascular Portfolio | no data | US$6.55m | 0.0021% $ 2.3m | |
| Executive VP & President of Neuroscience Portfolio | 5yrs | US$6.44m | 0.00092% $ 992.4k | |
| Executive Vice President of Global Operations & Supply Chain | 3.6yrs | US$7.66m | 0.0015% $ 1.6m | |
| Senior Vice President of Global Financial Planning and Analysis & Interim CFO | less than a year | sin datos | 0.00045% $ 485.4k | |
| Senior Vice President of Global Operations and Business Services | 8.1yrs | sin datos | sin datos | |
| Senior VP | 3.4yrs | sin datos | 0.0022% $ 2.4m | |
| Senior VP and Chief Technology & Innovation Officer | 1.4yrs | sin datos | sin datos | |
| Senior VP and Chief Scientific & Medical Officer | 2.6yrs | sin datos | sin datos | |
| VP & Head of Investor Relations | 9.4yrs | sin datos | sin datos | |
| Executive VP | 2.8yrs | US$11.72m | 0.0019% $ 2.0m | |
| Senior VP & Chief Communications Officer | 3.8yrs | sin datos | sin datos |
3.6yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MDT se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board & CEO | 5yrs | US$20.08m | 0.0060% $ 6.5m | |
| Independent Director | 11.8yrs | US$365.06k | 0.0012% $ 1.3m | |
| Independent Director | 17.8yrs | US$350.06k | 0.0015% $ 1.6m | |
| Independent Director | 9.8yrs | US$385.06k | 0.0034% $ 3.6m | |
| Lead Independent Director | 9.8yrs | US$410.06k | 0.0028% $ 3.0m | |
| Independent Director | 5.7yrs | US$370.06k | 0.00048% $ 517.8k | |
| Independent Director | 10.8yrs | US$370.06k | 0.0010% $ 1.1m | |
| Independent Director | 2.4yrs | US$350.06k | 0.00012% $ 129.4k | |
| Independent Director | 4.2yrs | US$370.06k | 0.00032% $ 345.2k | |
| Independent Director | 1.4yrs | US$306.97k | 0% $ 0 |
7.8yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de MDT se considera experimentada (7.8 años de antigüedad promedio).